Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

被引：111

作者：

Blandini, F

Armentero, MT

Fancellu, R

Blaugrund, E

Nappi, G

机构：

[1] Univ Pavia, Neurol Inst C Mondino, Lab Funct Neurochem, I-27100 Pavia, Italy

[2] Univ Insubria, Varese, Italy

[3] TEVA Pharmaceut Ind Ltd, Netanya, Israel

[4] Univ Roma La Sapienza, Dept Neurol & Otorhinolaryngol, Rome, Italy

来源：

EXPERIMENTAL NEUROLOGY | 2004年 / 187卷 / 02期

关键词：

6-hydroxydopamine; tyrosine bydroxylase; striatum; substantia nigra;

D O I：

10.1016/j.expneurol.2004.03.005

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Sprague-Dawley rats received a unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum and were treated daily for 6 weeks with increasing doses of monoamine oxidase type B inhibitor rasagiline [R(+)-N-propargyl-l-aminoindane] or saline (controls). Both doses of rasagiline markedly increased the survival of dopaminergic neurons in the lesioned substantia nigra, compared to controls (+97% and +119%, respectively). Treatment with the lower dose of rasagiline also abolished the motor stereotypies associated with nigrostriatal lesion. Our study supports the neuroprotective potential of chronic rasagiline administration in an experimental model of Parkinson's disease (PD). (C) 2004 Elsevier Inc. All rights reserved.

引用

收藏

页码：455 / 459

页数：5

相关论文

共 26 条

[1] Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells [J].

Abu-Raya, S ;

Tabakman, R ;

Blaugrund, E ;

Trembovler, V ;

Lazarovici, P .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 434 (03) :109-116

[2] Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan [J].

Akao, Y ;

Maruyama, W ;

Shimizu, S ;

Yi, H ;

Nakagawa, Y ;

Shamoto-Nagai, M ;

Youdim, MBH ;

Tsujimoto, Y ;

Naoi, M .

JOURNAL OF NEUROCHEMISTRY, 2002, 82 (04) :913-923

[3] An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells [J].

Akao, Y ;

Maruyama, W ;

Yi, H ;

Shamoto-Nagai, M ;

Youdim, MBH ;

Naoi, M .

NEUROSCIENCE LETTERS, 2002, 326 (02) :105-108

[4] Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline [J].

Bar Am, O ;

Amit, T ;

Youdim, MBH .

NEUROSCIENCE LETTERS, 2004, 355 (03) :169-172

[5] Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease [J].

Blum, D ;

Torch, S ;

Lambeng, N ;

Nissou, MF ;

Benabid, AL ;

Sadoul, R ;

Verna, JM .

PROGRESS IN NEUROBIOLOGY, 2001, 65 (02) :135-172

[6] CHRONIC CLORGYLINE AND PARGYLINE INCREASE APOMORPHINE-INDUCED STEREOTYPY IN THE RAT [J].

CAMPBELL, IC ;

DURCAN, MJ ;

COHEN, RM ;

PICKAR, D ;

CHUGANI, D ;

MURPHY, DL .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1985, 23 (06) :921-925

[7] Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat [J].

Carrillo, MC ;

Minami, C ;

Kitani, K ;

Maruyama, W ;

Ohashi, K ;

Yamamoto, Y ;

Naoi, M ;

Kanai, S ;

Youdim, MBH .

LIFE SCIENCES, 2000, 67 (05) :577-585

[8] Modeling Parkinsn's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway [J].

Deumens, R ;

Blokland, A ;

Prickaerts, J .

EXPERIMENTAL NEUROLOGY, 2002, 175 (02) :303-317

[9]

Finberg J P, 1999, Adv Neurol, V80, P495

[10] Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours [J].

Finberg, JPM ;

Youdim, MBH .

NEUROPHARMACOLOGY, 2002, 43 (07) :1110-1118